Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer.

Author information

Affiliations

  • 1. Tumor Etiology and Screening Department of Cancer Institute and General Surger, the First Hospital of China Medical University, Shenyang, 110001, China.
      Authors
    • Wang D 1
    • Guo Q 1
    • Yuan Y 1
    • Gong Y 1
    (4 authors)

ORCIDs linked to this article

BMC Microbiology, 04 Jul 2019, 19(1):152
https://doi.org/10.1186/s12866-019-1517-4 PMID: 31272365 PMCID: PMC6611032

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Background

H. pylori exhibits antibiotic resistance with regional differences. In this paper, we explored antibiotic resistance of H. pylori to five antibiotics in an area with a high risk of gastric cancer.

Results

H. pylori resistance rates to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were 78.0, 56.0, 31.0, 9.0, and 15.0%, respectively. Double, triple, quadruple, and quintuple resistance rates were 23, 20, 6, and 4%, respectively. The clarithromycin and multidrug resistance rates were significantly higher in males than females (clarithromycin: 44.4% vs 15.2%, respectively, P = 0.002; multidrug: 75.5% vs 37.2%, respectively; P < 0.001). During the three periods of 1998-1999, 2002-2004 and 2016-2017, the resistance rates to levofloxacin and amoxicillin were increasing (OR: 2.089, 95%CI: 1.142-3.821, P = 0.017; and OR: 5.035, 95%CI: 1.327-19.105, P = 0.018, respectively). The antibiotic resistance rates were unassociated with the host disease state. Metronidazole resistance was lower in the vacAs1m1/m2 group than the vacAs1m1m2 group (65% vs 85.7%, respectively; P = 0.026). As for levofloxacin resistance, it was higher with cagA + than cagA- (60.9% vs 23.1%, respectively; P = 0.020) but lower with slyD+ than slyD- (41.4% vs 68.5%, respectively; P = 0.009). Clarithromycin had a lower resistance rate with iceA++ than iceA-+ (19.7% vs 52.4%, respectively; P = 0.017). For amoxicillin, the iceA++ group had a lower resistance rate than the iceA-- group (1.6% vs 27.8%, respectively; P = 0.009).

Conclusions

The total resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were high in Zhuanghe. The resistanc rates to levofloxacin and amoxicillin increased over time. Clarithromycin resistance was associated with male and iceA. The resistance of metronidazole was related to vacA. Levofloxacin resistance was concerned with cagA and slyD and amoxicillin resistance was concerned with iceA. While, the antibiotic resistance of H. pylori had nothing to do with the status of gastric disease.

Free full text 

Logo of bmcmicrBioMed Central web sitethis articleSearchManuscript submissionRegistrationJournal front page
BMC Microbiol. 2019; 19: 152.
Published online 2019 Jul 4. https://doi.org/10.1186/s12866-019-1517-4
PMCID: PMC6611032
PMID: 31272365

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer

Dan Wang,1,2,3 Qianqian Guo,1,2,3 Yuan Yuan,corresponding author1,2,3 and Yuehua Gongcorresponding author1,2,3
Author information Article notes Copyright and License information Disclaimer

Associated Data

Data Availability Statement

Abstract

Background

H. pylori exhibits antibiotic resistance with regional differences. In this paper, we explored antibiotic resistance of H. pylori to five antibiotics in an area with a high risk of gastric cancer.

Results

H. pylori resistance rates to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were 78.0, 56.0, 31.0, 9.0, and 15.0%, respectively. Double, triple, quadruple, and quintuple resistance rates were 23, 20, 6, and 4%, respectively. The clarithromycin and multidrug resistance rates were significantly higher in males than females (clarithromycin: 44.4% vs 15.2%, respectively, P = 0.002; multidrug: 75.5% vs 37.2%, respectively; P < 0.001). During the three periods of 1998–1999, 2002–2004 and 2016–2017, the resistance rates to levofloxacin and amoxicillin were increasing (OR: 2.089, 95%CI: 1.142–3.821, P = 0.017; and OR: 5.035, 95%CI: 1.327–19.105, P = 0.018, respectively). The antibiotic resistance rates were unassociated with the host disease state. Metronidazole resistance was lower in the vacAs1m1/m2 group than the vacAs1m1m2 group (65% vs 85.7%, respectively; P = 0.026). As for levofloxacin resistance, it was higher with cagA + than cagA− (60.9% vs 23.1%, respectively; P = 0.020) but lower with slyD+ than slyD− (41.4% vs 68.5%, respectively; P = 0.009). Clarithromycin had a lower resistance rate with iceA++ than iceA−+ (19.7% vs 52.4%, respectively; P = 0.017). For amoxicillin, the iceA++ group had a lower resistance rate than the iceA−− group (1.6% vs 27.8%, respectively; P = 0.009).

Conclusions

The total resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were high in Zhuanghe. The resistanc rates to levofloxacin and amoxicillin increased over time. Clarithromycin resistance was associated with male and iceA. The resistance of metronidazole was related to vacA. Levofloxacin resistance was concerned with cagA and slyD and amoxicillin resistance was concerned with iceA. While, the antibiotic resistance of H. pylori had nothing to do with the status of gastric disease.

Keywords: H. pylori, Antibiotic resistance, Virulence factors, High-risk area of gastric cancer

Background

A number of large randomized controlled trials have shown that the eradication of Helicobacter pylori (H.pylori) can reduce the occurrence of chronic atrophic gastritis and intestinal metaplasia [1] and decrease the risk of gastric cancer [2]. Therefore, the successful eradication of H. pylori is of great significance for the prevention and treatment of gastric diseases. The antibiotics that are commonly used for H. pylori eradication include clarithromycin, metronidazole, amoxicillin, and levofloxacin. In the past few decades, the resistance rate has continued to increase.

The antibiotic resistance of H. pylori exhibits regional differences. In Germany [3] and Brazil [4], the antibiotic resistance rate to clarithromycin was 28.7 and 23.2%, respectively, and it was only 7.3% in Ireland [5] and 0% in Malaysia [6]. The resistance rate to levofloxacin was 32.7% in Buenos Aires [7] and 18.2% in the Bogota-Colombia [8], as well as 5.8% in the Hebei Province of China [9]. As reported in the literature, the resistance rate to amoxicillin and tetracycline is generally low [7, 10, 11], but in Ireland and Vietnam, it was as high as 38.1% [5] and 23.8% [12], respectively.

There are many factors influencing the antibiotic resistance of H. pylori, including age and gender, as well as the host disease status and virulence factors carried by the pathogens. However, there is no consistent report on whether these factors are related to the antibiotic resistance of H. pylori. It is well known that the virulence factors secreted by H. pylori are closely related to different clinical outcomes in gastric diseases. Cytotoxin-associated gene A (cagA) is the most common virulence factor of H. pylori. Some studies have shown that the clarithromycin resistance rate is higher in patients with cagA+ than those with cagA− [13], but others have demonstrated that the eradication rate in patients with cagA+ was significantly higher than those with cagA− [14]. These studies showed that the influencing factors of H. pylori antibiotic resistance are different. Therefore, it is necessary to carry out further investigations in different areas.

Zhuanghe, Liaoning Province, a high-risk area for gastric cancer, is in northern China. The H. pylori infection rate for the local residents was more than 60%, and the risk of gastric cancer and precancerous diseases was increased for H. pylori–infected individuals [15]. In this study, we investigated the antibiotic resistance of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline, aimed to provide guidance for the selection of medication, to improve the eradication effect, and to reduce the occurrence of gastric disease.

Methods

Patients

A total of 100 strains were collected from the primary cultures of 454 gastric mucosal tissues obtained during an endoscopic biopsy that were all from the Zhuanghe Gastric Diseases Screening Program, started in 1997 [15]. The gastric mucosal tissues were cultured for H.pylori during the 3 periods of 1998–1999, 2002–2004, 2016–2017 were 102, 242 and 110 cases. The number of primary cultured strains was 23, 50, and 27, respectively, so the total number of specimens in the 3 years was 100 strains. The patients were 54 males and 46 females, ranging from 24 to 87 years old (mean age: 50.74 ± 10.942 years). Pathological diagnosis was based on the updated Sydney Classification System, including 21 cases of superficial gastritis (GS), 35 cases of atrophic gastritis (GA), 32 cases of gastric erosion ulcer (GEU), 7 cases of atypical dysplasia (GD), and 5 cases of gastric cancer (GC). Patients were excluded if they had stomach surgery and if they were administered eradication treatment. The study was approved by the Ethics Committee of Chinese Medical University and all participants signed an informed consent.

Antibiotic susceptibility testing

The susceptibility of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline was tested using an Epsilometer test (E-test, bioMerieux, France). The methods of H.pylori culture and antibiotic susceptibility testing are all the same in different periods. The H. pylori that was in a logarithmic growth period was adjusted to a McFarland standard of 2.0 and smeared evenly with a sterile cotton swab (bioMerieux, France) on Mueller-Hinton agar (Oxoid, Basingstoke, UK), supplemented with 7% defibrinated sheep blood. The concentration range of the E-test strips was 0.016–256 μg/ml for metronidazole, amoxicillin, and tetracycline (bioMerieux, France); 0.016–256 μg/ml for clarithromycin; and 0.016–32 μg/ml for levofloxacin (Kangtai, China). Then, the plates were incubated at 37 °C for 48–72 h in a microaerophilic atmosphere with 10% O2, 5% CO2, and 85% N2. Thereafter, the minimum inhibitory concentration (MIC) for each antibiotic was determined after 48–72 h by two people independently. The MIC breakpoints were identified using the recommended Clinical and Laboratory Standards Institute (http://www.clsi.org/) of America. Strains were considered resistant with an MIC of ≥1 mg/ml for clarithromycin [16], levofloxacin [17], amoxicillin and tetracycline [18] and ≥ 8 mg/ml for metronidazole [4]. The H. pylori reference strain, ATCC 26695, was used for quality control.

DNA extraction

Whole genomic DNA of H. pylori was extracted using a phenol-chloroform method [15]. In brief, 300 μl of TE buffer (10 Mm Tris-HCl [pH 8.3], 0.1 mmol/l EDTA), 100 μl of 10% SDS, and 10 μl of PK enzyme (20 mg/ml) were added to the bacterial precipitate and digested overnight in a water bath at 55 °C. The extracted DNA was dissolved in 50–100 μl of TE buffer and stored at − 20 °C.

Polymerase chain reaction amplification of H. pylori virulence genes

H. pylori virulence factors cagA, vacA (s1, s2, m1a, m1b, m2, i1, and i2), iceA1, iceA2, babA2, oipA, slyD, hrgA, and cagA-EPIYA motif were amplified using polymerase chain reaction (PCR) [19–26]. The 25-μl amplification system included 2 mmol/L dNTP, 2.5 U Taq DNA polymerase, 10 × buffer (Takara, China), 10 pmol primer, and 1 μl of DNA template. The amplified products were identified using 2% agarose gel electrophoresis. Both positive and negative controls were performed in parallel for each PCR reaction.

Statistical analysis

All statistical analysis was carried out using SPSS V.18.0 software for Windows (SPSS Inc., Chicago, IL, USA). A binary logistic regression model was used to calculate the odds ratios (OR) and 95% confidence interval (CI). A P value of < 0.05 was defined as significant.

Results

The characteristics of H. pylori antibiotic resistance

First, we detected the drug resistance of 100 H. pylori strains to the five previously mentioned antibiotics using E-test. The results showed that the total resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were 78.0% (78/100), 56.0% (56/100), 31.0% (31/100), 9.0% (9/100), and 15.0% (15/100), respectively (Figs. ​(Figs.11 and ​and2).2). Further analysis revealed that H. pylori resistance occurred at high MIC levels. In the metronidazole-resistant strains, 89.7% (70/78) of the MIC values were more than 64 μg/ml and 83.3% (65/78) exceeded 256 μg/ml (Fig. ​(Fig.1a).1a). In the levofloxacin-resistant strains, 51.8% (29/56) of the MIC values were 32 μg/ml (Fig. ​(Fig.1b).1b). Among the strains resistant to clarithromycin, 80.6% (25/31) of the MIC values were above 256 μg/ml (Fig. ​(Fig.2a).2a). If stratified by gender and age, we found that the clarithromycin resistance rate was significantly higher for males than females (44.4% vs 15.2%, respectively; OR: 4.457, 95%CI: 1.694–11.724; P = 0.002). There was no significant difference for the resistance rates of the four other antibiotics by gender. Further, no significant difference was demonstrated in the resistance rates for the five antibiotics by age (Table 1).

An external file that holds a picture, illustration, etc. Object name is 12866_2019_1517_Fig1_HTML.jpg

Distribution of the antibiotic (a for metronidazole, b forlevofloxacin), MIC values for the H. pylori isolates in Zhuanghe

An external file that holds a picture, illustration, etc. Object name is 12866_2019_1517_Fig2_HTML.jpg

Distribution of the antibiotic (a for clarithromycin, b for amoxicillin, and c for tetracycline). MIC values for the H. pylori isolates in Zhuanghe

Table 1

The Characteristic of antibiotic resistance of H. pylori isolates in Zhuanghe

CharacteristicNMNZCAMLVXAMXTCN
OR(95%CI)P valueOR(95%CI)P valueOR(95%CI)P valueOR(95%CI)P valueOR(95%CI)P value
Age
≤ 60 vs > 6017 vs 830.420 (0.088–1.996)0.275 0.581 (0.198–1.705) 0.323 1.160 (0.407–3.305)0.7801.778 (0.207–15.236)0.60.824 (0.205–3.306)0.784
Gender
Female vs male46 vs 541.553 (0.600–4.020)0.364 4.457 (1.694–11.724) 0.002 1.571 (0.709–3.483)0.2661.745 (0.410–7.422)0.4512.619 (0.770–8.903)0.123
Clinical outcome
GEU vs NGEU32 vs 631.006 (0.318–3.182)0.992 0.857 (0.325–2.261) 0.756 0.613 (0.242–1.553)0.3021.180 (0.252–5.537)0.8341.886 (0.504–7.056)0.346
GA vs GS36 vs 204.356 (0.854–22.223)0.077 0.258 (0.058–1.138) 0.073 0.608 (0.202–1.832)0.3770.301 (0.032–2.808)0.2921.567 (0.342–7.180)0.563
GEU vs GS32 vs 201.683 (0.496–5.709)0.403 0.632 (0.201–1.982) 0.431 1.694 (0.586–4.898)0.330.534 (0.101–2.816)0.460.74 (0.162–3.417)0.704
GEU vs GA32 vs 360.463 (0.063–3.395)0.449 3.182 (0.563–17.972) 0.19 2.197 (0.628–7.691)0.2180.966 (0.074–12.669)0.9790.214 (0.034–1.368)0.103
Year
1998 to 20171001.276 (0.638–2.551)0.491 1.543 (0.823–2.892) 0.176 2.089 (1.142–3.821) 0.017 5.035 (1.327–19.105) 0.018 1.161 (0.540–2.499)0.702
Virulence factors
cagA- vs cagA+13 vs 871.509 (0.409–5.561)0.537 2.192 (0.427–11.235) 0.347 5.133 (1.297–20.319) 0.02 00.99900.999
babA2- vs babA2+18 vs 821.374 (0.423–4.456)0.597 0.822 (0.257–2.627) 0.741 0.789 (0.276–2.303)0.6760.854 (0.158–4.634)0.8551.606 (0.316–8.159)0.568
hrgA- vs hrgA+43 vs 570.518 (0.188–1.431)0.205 0.419 (0.166–1.059) 0.066 0.708 (0.315–1.591)0.4031.839 (0.458–7.385)0.3911.749 (0.569–5.376)0.329
slyD- vs slyD+54 vs 460.519 (0.196–1.376)0.187 0.585 (0.233–1.470) 0.254 0.334 (0.146–0.764) 0.009 0.144 (0.017–1.205)0.0740.883 (0.282–2.765)0.831
opiA- vs opiA+33 vs 670.435 (0.141–1.340)0.147 1.163 (0.424–3.193) 0.769 0.501 (0.203–1.236)0.1330.404 (0.100–1.632)0.2030.557 (0.179–1.731)0.312
vacAi1- vs vacAi1+36 vs 640.490 (0.161–1.494)0.21 0.448 (0.174–1.154) 0.096 0.891 (0.380–2.092)0.7910.427 (0.106–1.720)0.2310.589 (0.190–1.824)0.359
vacAs1m1m2 vs vacAs1m1/m242 vs 40 0.287 (0.096–0.863) 0.026 0.763 (0.287–2.027) 0.588 0.749 (0.311–1.804)0.520.434 (0.078–2.420)0.3410.758 (0.215–2.667)0.666
iceA-- vs iceA−+18 vs 210.505 (0.071–3.612)0.496 1.476 (0.369–5.902) 0.582 0.572 (0.135–2.415)0.4470.489 (0.090–2.649)0.4061.096 (0.222–5.418)0.91
iceA-- vs iceA++18 vs 610.317 (0.065–1.557)0.157 0.310 (0.094–1.020) 0.054 0.428 (0.134–1.367)0.152 0.051 (0.005–0.481) 0.009 0.450 (0.106–1.900)0.277
iceA− + vs iceA++21 vs 610.474 (0.122–1.847)0.282 0.234 (0.071–0.775) 0.017 0.812 (0.294–2.240)0.6880.101 (0.009–1.086)0.0590.388 (0.099–1.527)0.176

In addition, among the 100 strains of H. pylori, 39 (39%) had single-drug resistance, 23 (23%) had double-drug resistance, and 20 (20%) had triple-drug resistance; meanwhile, 6 (6%) were resistant to four drugs, and 4 (4%) were resistant to all five antibiotics (Table 2). Only 8 (8%) strains were found to be sensitive to all five antibiotics. As for the multidrug-resistant strains, most were double or triple resistant. The highest proportion of a double-drug resistant pattern was metronidazole plus levofloxacin, accounting for 73.9%. The highest proportion of a triple-drug resistance pattern was the combination of metronidazole, levofloxacin, and clarithromycin, accounting for 55%. Similarly, after stratifying by gender and age, the results showed that the multidrug resistance rate was higher for males than females (75.5% vs 37.2%, respectively; OR: 5.203, 95%CI: 2.120–12.771, P < 0.001, Table ​Table1).1). However, there was no significant difference between the single and multidrug resistance rates based on age.

Table 2

Distribution of resistance patterns among H. pylori strains

Susceptibility test resultsN
Sensitive to all ABs8
Single39
MNZ26
LVX9
CAM3
AMX0
TCN1
Double23
MNZ + LVX17
MNZ + CAM5
LVX + CAM1
Triple20
MNZ + LVX + CAM11
MNZ + LVX + TCN6
MNZ + LVX + AMX2
MNZ + CAM + AMX1
Quadruple6
MNZ + LVX + CAM + AMX2
MNZ + LVX + CAM + TCN4
Resistance to all ABs4

Abbreviations: AB antibiotic

The changing profile of H. pylori antibiotic resistance during the past three decades

In this study, we compared the changing profile of H. pylori resistance in the Zhuanghe area during three decades from 1998 to 2017 (Fig. ​(Fig.3).3). During the three periods, 1998–1999, 2002–2004 and 2016–2017, the resistance rate to certain antibiotics was as follows: metronidazole was 87.0, 66.0 and 92.6%, respectively; levofloxacin was 47.8, 46.0 and 81.5%, respectively; clarithromycin was 39.1, 14.0 and 55.6%, respectively; amoxicillin was 4.3, 2.0 and 25.9%, respectively; and tetracycline was 13.0, 14.0 and 18.5%, respectively. Adjusting for age and gender, we found that the resistance rates to metronidazole, clarithromycin, and tetracycline were not significant over the three decades (Table ​(Table1),1), but the resistant rates to levofloxacin and amoxicillin increased (OR: 2.089, 95%CI: 1.142–3.821, P = 0.017, respectively; OR: 5.035, 95%CI: 1.327–19.105, P = 0.018, respectively). In addition, we analyzed the changing profile for the single-drug or multidrug resistance rates over the three decades (Table 1) that showed that the rate of single-drug resistance decreased (OR: 0.411, 95%CI: 0.205–0.824, P = 0.012), but the multidrug resistance increased (OR: 2.059, 95%CI: 1.090–3.889, P = 0.026).

An external file that holds a picture, illustration, etc. Object name is 12866_2019_1517_Fig3_HTML.jpg

The changing profile for H. pylori antibiotic resistance during the three decades

The antibiotic resistance of H. pylori and host disease state

Concerning the relationship between H. pylori antibiotic resistance and host disease status, we found that after adjusting for age and gender, there was no significant difference in the antibiotic resistance for the GS, GA, and GEU groups or the GEU and non-gastric erosion ulcer (NGEU) groups (Table ​(Table11).

The antibiotic resistance of H. pylori and virulence factor

The virulence factors cagA, vacA (s1, m1, m2, and 1), iceA1, iceA2, babA2, oipA, slyD, and hrgA and their correlations with the five types of antibiotic resistance were calculated by a binary logistic regression analysis (Table ​(Table1).1). The results showed that the resistance rate to metronidazole was lower in the vacAs1m1/m2 group than the vacAs1m1m2 group (65% vs 85.7%, respectively; OR: 0.287, 95%CI: 0.096–0.863, P = 0.026) after adjusting for age and gender. As for the resistance rate to levofloxacin, it was higher in the cagA + group than the cagA− group (60.9% vs 23.1%, respectively; OR: 5.133, 95% CI: 1.297–20.319, P = 0.020) but was lower in the slyD+ group than the slyD− group (41.4% vs 68.5%, respectively; OR: 0.334, 95%CI: 0.146–0.764, P = 0.009). A lower resistance rate to clarithromycin was observed in the iceA++ group than the iceA- + group (19.7% vs 52.4%, respectively; OR: 0.234, 95%CI: 0.071–0.775, P = 0.017). As for amoxicillin, the iceA++ group had a lower resistance rate than the iceA−− group (1.6% vs 27.8%, respectively; OR: 0.051, 95%CI: 0.005–0.481, P = 0.009). There was no significant difference in the relationship between the other H. pylori virulence factors such as vacA, babA, oipA, and hrgA and antibiotic resistance (P > 0.05). In addition, to detect the EPIYA motif classifications for the cagA+ (n = 87) group, we found that it was mainly composed of East Asian type EPIYA-ABD (n = 79), western type EPIYA-ABC (n = 2), mixed type EPIYA-ABCD (n = 5), and one EPIYA-ACD. Because of the small number of cases in the different groups, the statistical relationships for antibiotic resistance cannot be analyzed.

Discussions

Antibiotic resistance is the main reason for failure to eradicate an H. pylori infection. In this study, 100 H. pylori strains from Zhuanghe, an area with a high incidence of GC, were included to investigate the antibiotic resistance, to explore the trend over time, and to analyze the factors affecting antibiotic resistance. This study revealed the antibiotic resistance of H. pylori to five antibiotics in an area with a high incidence of GC and provided guidance for the treatment of H. pylori.

Our study demonstrated that the total resistance rates of H. pylori to metronidazole, levofloxacin, and clarithromycin were 78, 56, and 31%, respectively, with high MIC levels; however, the resistance rates to amoxicillin and tetracycline were low, and the multidrug resistance rate was as high as 53%. As compared with low-risk areas for GC in China [27–29], neighboring countries [30–33], and other non-neighboring countries [6, 11, 34, 35], the antibiotic resistance was generally higher in the Zhuanghe area. The high antibiotic resistance increased the risk of H. pylori transmission among the population and caused a widespread and persistent high infection rate of H. pylori in the population; moreover, it also could increase the continued colonization of the stomach in hosts and increase the inflammation of and damage to the gastric mucosa, which may lead to an increased risk of GC.

According to previous studies, H. pylori antibiotic resistance has significantly changed over time [8, 33, 36–38]. For example, in Korea, the resistance rate to clarithromycin increased from 11 to 60% from 2009 to 2014 [39, 40]. In Singapore, the resistance rate to metronidazole increased from 24.8 to 48.2% from 2000 to 2014 [38]. Our results showed that the resistance rates to clarithromycin and metronidazole maintained a stable yet high level and that tetracycline was at a steady yet low level in 1998–2017. The resistance rates to levofloxacin and amoxicillin, as well as multidrug resistance, have demonstrated an increasing trend. Our study showed that the two antibiotics, clarithromycin and metronidazole, were not suitable for eradication therapy in this area. However, tetracycline can be used to eradicate H. pylori but has a shortcoming because of adverse reactions, so the time and dose should be strictly controlled. Developing alternative drugs to help with eradication is also a future goal.

In this study, we found that the resistance rate to clarithromycin for males was significantly higher than females. Boyanova [41] also had similar conclusions in females and males. In addition, we found males are more prone to multidrug resistance than females. The possible causes of this phenomenon was that macrolide antibiotics were commonly used for the treatment of respiratory diseases and respiratory infections related to smoking and other factors mostly occurred in men that might lead to antibiotic resistance for males with a clarithromycin-based eradication treatment for H. pylori. Previous studies of our group showed that the incidence and mortality of males with GC in the Zhuanghe area were higher than those of females by 2.8 times and 2.3 times, respectively [42]. Thus, the high antibiotic resistance of H. pylori for males might also be one risk factor for GC in addition to environmental exposure factors such as diet, smoking, drinking, and occupation.

In addition, there have been different reports on whether the gastric disease status is related to the antibiotic resistance of H. pylori. A study involving 2751 patients in France showed that the successful eradication rate of H. pylori in patients with a duodenal ulcer was higher than that of patients with a non-ulcer-related dyspepsia [43]. However, some medical literature indicated that these diseases are not related to antibiotic resistance [30, 41, 44–47]. In the present study, we found that the H. pylori resistance rate was not associated with gastric disease. However, while analyzing the reason, on the one hand, it may be geographical differences. On the other hand, it may be because of the small number of cases included in this study.

Some virulence factors carried by H. pylori may also affect the clinical outcomes of eradication [48–50]. As compared with single- and multi-strain infections, we found that the resistance rate of metronidazole to vacAm1 or vacAm2 was lower than that of a mixed infection with vacAm1m2, to iceA1 or iceA2 alone higher than that of mixed infection with iceA1A2. The resistance rate to amoxicillin in iceA−− was higher than that of a mixed infection. Additionally, the resistance rate to levofloxacin was higher in the cagA + group than the cagA− one. The resistance rate to levofloxacin was higher in the slyD− group than the slyD+ one. CagA+ or mixed vacAs1m1m2 infection was associated with antibiotic resistance. Patients infected with such strains had more difficulty achieving eradication of H. pylori, and continuous colonization was more likely to induce precancerous lesions and GC. Therefore, decreasing the incidence of GC could be achieved so long as the emergence of antibiotic resistance is avoided during the administration of effective eradication treatment. In addition, a mixed iceA or slyD+ strain would be easy to eradicate according to the present study results. However, in some reports both iceA1 and iceA2 infections were unrelated to the eradication outcomes [51, 52]. SlyD was a new virulence factor associated with gastric disease [53]. To our knowledge, until now, there was no report on the relationship between slyD and antibiotic resistance. Therefore, the relationship between these two virulence factors and bacterial resistance needs to be further explored.

This study had the following limitations: 1. Since there exists dominant genotype of H.pylori virulence factors eg. cagA positive, vacA s1 m1, and iceA1 positive in this area [15], therefore, the relationship between virulence factors and antibiotic resistance needs to be further investigated. 2. The obtained conclusions in the present study were based in a number of only 100 strains, the factors affecting the antibiotic resistance still needs to further verification in a large samples. 3. Other factors such as host CYP2C19, MDR, and IL-1β gene polymorphism can also influence H. pylori eradication. However, there is a lack of relevant information in our study, so we could not evaluate it.

Conclusions

In conclusion, our study evaluated the antibiotic resistance and influencing factors of H. pylori in Zhuanghe. The total resistance rates to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were high. The resistance rates to levofloxacin and amoxicillin increased over time. Clarithromycin resistance was associated with male and iceA. The resistance of metronidazole was related to vacA. Levofloxacin resistance was concerned with cagA and slyD and amoxicillin resistance was concerned with iceA. While, the antibiotic resistance of H. pylori had nothing to do with the status of gastric disease. Per this study, clarithromycin-based triple therapy is no longer applicable in this area; metronidazole and levofloxacin should be used with high vigilance; and amoxicillin and tetracycline can be used as candidates for antibiotic treatment. Virulence factors including cagA, vacA, iceA, and slyD can be used to predict antibiotic resistance. Our study is beneficial to the selection of the H. pylori eradication program that is conducive to reducing the infection rate, thus helping in the prevention and treatment of GC and related gastric diseases.

Acknowledgements

Not applicable.

Abbreviations

AMXAmoxicillin
CAMCalrithromycin
GAAtrophic gastritis
GCGastric cancer
GDAtypical dysplasia
GEUGastric erosion ulcer
GSSuperficial gastritis
LVXLevofloxacin
MICMinimum inhibitory concentration
MNZMetronidazole
NGEUNon-gastric erosion ulcer (NGEU)
TCNTetracycline

Authors’ contributions

YY and YHG designed the experiment. DW conducted the experiment. DW and YHG analysed the samples and performed data analysis. DW produced the first draft of the manuscript and QQG contributed to drafting and editing the manuscript. All the authors have read and approved the final version of the manuscript.

Funding

This work was supported by the National Key R&D Program of China (Grant No.2017YFC0908300) and Natural Science Foundation of Liaoning Province (Grant No. 201602822). The design of this study, sample collections and data analysis were supported by Grant No.2017YFC0908300. The writing of this manuscript was aided by Grant No. 201602822.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Chinese Medical University and all participants signed an informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Dan Wang, moc.361@1991elaDW.

Qianqian Guo, moc.621@5221tnelat.

Yuan Yuan, nc.ude.umc@nauynauy.

Yuehua Gong, nc.ude.umc@gnoghy.

References

1. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98(14):974–983. 10.1093/jnci/djj264. [Abstract] [CrossRef] [Google Scholar]
2. Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K, et al. Seventeen-year effects of eradicating helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol. 2015;50(6):638–644. 10.1007/s00535-014-1004-5. [Abstract] [CrossRef] [Google Scholar]
3. Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in Southwest Germany. Helicobacter. 2017;22(1):e12327. 10.1111/hel.12327. [Abstract] [CrossRef] [Google Scholar]
4. Ogata SK, Godoy AP, da Silva Patricio FR, Kawakami E. High helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56(6):645–648. 10.1097/MPG.0b013e31828b3669. [Abstract] [CrossRef] [Google Scholar]
5. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch Iran Med. 2010;13(3):177–187. [Abstract] [Google Scholar]
6. Goh KL, Navaratnam P. High helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter. 2011;16(3):241–245. 10.1111/j.1523-5378.2011.00841.x. [Abstract] [CrossRef] [Google Scholar]
7. Zerbetto De Palma G, Mendiondo N, Wonaga A, Viola L, Ibarra D, Campitelli E, et al. Occurrence of mutations in the antimicrobial target genes related to levofloxacin, clarithromycin, and amoxicillin resistance in helicobacter pylori Isolates from Buenos Aires City. Microb Drug Resist. 2017;23(3):351–358. 10.1089/mdr.2015.0361. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
8. Trespalacios-Rangel AA, Otero W, Arevalo-Galvis A, Poutou-Pinales RA, Rimbara E, Graham DY. Surveillance of levofloxacin resistance in helicobacter pylori isolates in Bogota-Colombia (2009-2014) PLoS One. 2016;11(7):e0160007. 10.1371/journal.pone.0160007. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
9. Meng X, Liu G, Wu J, Kong C, Zhao L, Zhu X, et al. Antibiotic resistance of helicobacter pylori clinical isolates in Hebei Province. Zhonghua Yi Xue Za Zhi. 2016;96(4):270–272. [Abstract] [Google Scholar]
10. Miftahussurur M, Cruz M, Subsomwong P, Jimenez Abreu JA, Hosking C, Nagashima H, et al. Clarithromycin-based triple therapy is still useful as an initial treatment for helicobacter pylori infection in the Dominican Republic. Am J Trop Med Hyg. 2017;96(5):1050–1059. [Europe PMC free article] [Abstract] [Google Scholar]
11. Macías-García Fernando, Llovo-Taboada José, Díaz-López Mario, Bastón-Rey Iria, Domínguez-Muñoz Juan Enrique. High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain. Helicobacter. 2017;22(6):e12440. 10.1111/hel.12440. [Abstract] [CrossRef] [Google Scholar]
12. Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, et al. Antimicrobial susceptibility and clarithromycin resistance patterns of helicobacter pylori clinical isolates in Vietnam. F1000Research. 2016;5:671. 10.12688/f1000research.8239.1. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
13. Khan A, Farooqui A, Manzoor H, Akhtar SS, Quraishy MS, Kazmi SU. Antibiotic resistance and cagA gene correlation: a looming crisis of helicobacter pylori. World J Gastroenterol. 2012;18(18):2245–2252. 10.3748/wjg.v18.i18.2245. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
14. van der Hulst RW, van der Ende A, Dekker FW, Ten Kate FJ, Weel JF, Keller JJ, et al. Effect of helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113(1):25–30. 10.1016/S0016-5085(97)70076-3. [Abstract] [CrossRef] [Google Scholar]
15. Gong YH, Wang Y, Yuan Y. Distribution of helicobacter pylori in North China. World J Gastroenterol. 2005;11(23):3523–3527. 10.3748/wjg.v11.i23.3523. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
16. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, et al. Contribution of efflux pumps to clarithromycin resistance in helicobacter pylori. J Gastroenterol Hepatol. 2010;25(Suppl 1):S75–S79. 10.1111/j.1440-1746.2009.06220.x. [Abstract] [CrossRef] [Google Scholar]
17. Teh X, Khosravi Y, Lee WC, Leow AH, Loke MF, Vadivelu J, et al. Functional and molecular surveillance of helicobacter pylori antibiotic resistance in Kuala Lumpur. PLoS One. 2014;9(7):e101481. 10.1371/journal.pone.0101481. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
18. Wuppenhorst N, Lenze F, Ross M, Kist M. Isolation and eradication of a clinical isolate of helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother. 2011;66(1):222–223. 10.1093/jac/dkq405. [Abstract] [CrossRef] [Google Scholar]
19. Pan ZJ, van der Hulst RW, Feller M, Xiao SD, Tytgat GN, Dankert J, et al. Equally high prevalences of infection with cagA-positive helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol. 1997;35(6):1344–1347. [Europe PMC free article] [Abstract] [Google Scholar]
20. Atherton JC, Cao P, Peek RM, Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem. 1995;270(30):17771–17777. 10.1074/jbc.270.30.17771. [Abstract] [CrossRef] [Google Scholar]
21. Li Q, Zhu Y, Liu J, Yu X, Chen M, Dong N, et al. HpSlyD inducing CDX2 and VIL1 expression mediated through TCTP protein may contribute to intestinal metaplasia in the stomach. Sci Rep. 2017;7(1):2278. 10.1038/s41598-017-02642-y. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
22. G M, Tiwari SK, Sharma V, Habeeb MA, Khan AA, Cm H. Association of Helicobacter pylori restriction endonuclease-replacing gene, hrgA with overt gastrointestinal diseases. Arq Gastroenterol. 2008;45(3):225–229. 10.1590/S0004-28032008000300011. [Abstract] [CrossRef] [Google Scholar]
23. van Doorn LJ, Figueiredo C, Rossau R, Jannes G, van Asbroek M, Sousa JC, et al. Typing of helicobacter pylori vacA gene and detection of cagA gene by PCR and reverse hybridization. J Clin Microbiol. 1998;36(5):1271–1276. [Europe PMC free article] [Abstract] [Google Scholar]
24. Arevalo-Galvis A, Trespalacios-Rangell AA, Otero W, Mercado-Reyes MM, Poutou-Pinales RA. Prevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol J Microbiol. 2012;61(1):33–40. [Abstract] [Google Scholar]
25. Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 1991;19(24):6823–6831. 10.1093/nar/19.24.6823. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
26. Schmidt HM, Goh KL, Fock KM, Hilmi I, Dhamodaran S, Forman D, et al. Distinct cagA EPIYA motifs are associated with ethnic diversity in Malaysia and Singapore. Helicobacter. 2009;14(4):256–263. 10.1111/j.1523-5378.2009.00684.x. [Abstract] [CrossRef] [Google Scholar]
27. Han R, Lu H, Jiang MW, Tan KW, Peng Z, Hu JL, et al. Multicenter study of antibiotic resistance profile of H. pylori and distribution of CYP2C19 gene polymorphism in rural population of Chongqing, China. Gastroenterol Res Pract. 2016;2016:8547686. 10.1155/2016/8547686. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
28. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, et al. Antibiotic resistance of helicobacter pylori isolated in the southeast coastal region of China. Helicobacter. 2013;18(4):274–279. 10.1111/hel.12046. [Abstract] [CrossRef] [Google Scholar]
29. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, et al. The evolution of helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010;15(5):460–466. 10.1111/j.1523-5378.2010.00788.x. [Abstract] [CrossRef] [Google Scholar]
30. Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, et al. The incidence of primary antibiotic resistance of helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47(3):233–238. 10.1097/MCG.0b013e3182676e2b. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
31. Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, et al. Resistance of helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27(3):493–497. 10.1111/j.1440-1746.2011.06874.x. [Abstract] [CrossRef] [Google Scholar]
32. Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, et al. Antimicrobial resistance and characteristics of eradication therapy of helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19(3):214–220. 10.1111/hel.12124. [Abstract] [CrossRef] [Google Scholar]
33. Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, et al. Primary antibiotic resistance in helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):707–715. 10.1016/S2468-1253(17)30219-4. [Abstract] [CrossRef] [Google Scholar]
34. Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, et al. Antimicrobial resistance of helicobacter pylori strains to five antibiotics, including levofloxacin, in northwestern Turkey. Rev Soc Bras Med Trop. 2015;48(3):278–284. 10.1590/0037-8682-0027-2015. [Abstract] [CrossRef] [Google Scholar]
35. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol. 2015;13(9):1616–1624. 10.1016/j.cgh.2015.02.005. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
36. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19(4):409–414. [Abstract] [Google Scholar]
37. Kostamo P, Veijola L, Oksanen A, Sarna S, Rautelin H. Recent trends in primary antimicrobial resistance of helicobacter pylori in Finland. Int J Antimicrob Agents. 2011;37(1):22–25. 10.1016/j.ijantimicag.2010.09.013. [Abstract] [CrossRef] [Google Scholar]
38. Ang TL, Fock KM, Ang D, Kwek AB, Teo EK, Dhamodaran S. The changing profile of helicobacter pylori antibiotic resistance in Singapore: a 15-year study. Helicobacter. 2016;21(4):261–265. 10.1111/hel.12291. [Abstract] [CrossRef] [Google Scholar]
39. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, et al. Analysis of metronidazole, clarithromycin and tetracycline resistance of helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001;47(4):459–461. 10.1093/jac/47.4.459. [Abstract] [CrossRef] [Google Scholar]
40. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, et al. Change in antibiotic resistance of helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010;44(8):536–543. [Abstract] [Google Scholar]
41. Boyanova L, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, et al. Numerous risk factors for helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. J Med Microbiol. 2012;61(Pt 1):85–93. 10.1099/jmm.0.035568-0. [Abstract] [CrossRef] [Google Scholar]
42. Jing JJ, Liu HY, Hao JK, Wang LN, Wang YP, Sun LH, et al. Gastric cancer incidence and mortality in Zhuanghe, China, between 2005 and 2010. World J Gastroenterol. 2012;18(11):1262–1269. 10.3748/wjg.v18.i11.1262. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
43. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17(1):99–109. 10.1046/j.1365-2036.2003.01396.x. [Abstract] [CrossRef] [Google Scholar]
44. Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, et al. Surveillance of helicobacter pylori antibiotic susceptibility in Indonesia: different resistance types among regions and with novel genetic mutations. PLoS One. 2016;11(12):e0166199. 10.1371/journal.pone.0166199. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
45. Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, et al. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for helicobacter pylori infection. World J Gastroenterol. 2015;21(46):13124–13131. 10.3748/wjg.v21.i46.13124. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
46. Hirata Y, Serizawa T, Shichijo S, Suzuki N, Sakitani K, Hayakawa Y, et al. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line helicobacter pylori eradication regimen. Int J Infect Dis. 2016;51:66–69. 10.1016/j.ijid.2016.08.019. [Abstract] [CrossRef] [Google Scholar]
47. An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, et al. Antibiotic resistance in helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann Lab Med. 2013;33(6):415–419. 10.3343/alm.2013.33.6.415. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
48. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637–1650. 10.1517/14728222.2015.1073261. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
49. Van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WGV, De Boer WA. Importance of helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut. 2000;46(3):321–326. 10.1136/gut.46.3.321. [Europe PMC free article] [Abstract] [CrossRef] [Google Scholar]
50. Niu SL, Yang F. Relationship between lansoprasoi triple therapy effect and alleles of vacuolating cytotoxin genotype in patients with gastric ulcer. Chin J Pract Med. 2014;(41):02.
51. Scholte GH, van Doorn LJ, Cats A, Bloemena E, Lindeman J, Quint WG, et al. Genotyping of helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. Am J Gastroenterol. 2002;97(7):1687–1695. 10.1111/j.1572-0241.2002.05775.x. [Abstract] [CrossRef] [Google Scholar]
52. Russo F, Berloco P, Cuomo R, Caruso ML, Di Matteo G, Giorgio P, et al. Helicobacter pylori strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther. 2003;17(3):421–428. 10.1046/j.1365-2036.2003.01443.x. [Abstract] [CrossRef] [Google Scholar]
53. Kang D, Gong Y, Zhu Y, Li A, Dong N, Piao Y, et al. The biological activity of H. pylori SlyD in vitro. Helicobacter. 2013;18(5):347–355. 10.1111/hel.12057. [Abstract] [CrossRef] [Google Scholar]
Articles from BMC Microbiology are provided here courtesy of BMC

Full text links 

Read article at publisher's site: https://doi.org/10.1186/s12866-019-1517-4

Read article for free, from open access legal sources, via Unpaywall: https://bmcmicrobiol.biomedcentral.com/track/pdf/10.1186/s12866-019-1517-4Unpaywall

Citations & impact 

Impact metrics

40
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/63172667
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/63172667

Article citations

Go to all (40) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

National Key R&amp;D Program of China (1)

Natural Science Foundation of Liaoning Province (1)